Research3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial
ResearchComparative bone histomorphometry effects of combined denosumab and teriparatide vs monotherapy in postmenopausal women with osteoporosis: a randomized controlled trial
ResearchSafety of low dose inpatient zoledronic acid in acute hip fracture patients with advanced chronic kidney disease
ResearchRomosozumab improves microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis
ResearchDose-Specific Effects of Denosumab on Serum Calcium Levels in Patients With Osteoporosis and Various Renal Functions
ResearchThe comparative efficacy of 12-mo of alendronate and raloxifene in maintaining denosumab-induced improvement in peripheral volumetric BMD, microarchitecture, and estimated strength
ResearchA Fracture Liaison Service to Address Vitamin D Deficiency for Patients Hospitalized for Osteoporotic Fracture
ResearchEvaluation of Osteogenic Phenotype in Postmenopausal Women Receiving Anabolic and Antiresorptive Osteoporosis Therapies
ResearchThe comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial